Cover
Cover - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Feb. 24, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 001-34170 | ||
Entity Registrant Name | MicroVision, Inc. | ||
Entity Central Index Key | 0000065770 | ||
Entity Tax Identification Number | 91-1600822 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 18390 NE 68th Street | ||
Entity Address, City or Town | Redmond | ||
Entity Address, State or Province | WA | ||
Entity Address, Postal Zip Code | 98052 | ||
City Area Code | 425 | ||
Local Phone Number | 936-6847 | ||
Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
Trading Symbol | MVIS | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 635.3 | ||
Entity Common Stock, Shares Outstanding | 175,818,617 | ||
Documents Incorporated by Reference [Text Block] | Portions of the registrant’s definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Shareholders (the “2023 Proxy Statement”) are incorporated herein by reference in Part III of this Annual Report on Form 10-K | ||
ICFR Auditor Attestation Flag | true | ||
Auditor Name | Moss Adams LLP | ||
Auditor Location | Seattle, Washington | ||
Auditor Firm ID | 659 |
Balance Sheets
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash and cash equivalents | $ 20,536 | $ 82,647 |
Investment securities, available-for-sale | 62,173 | 32,720 |
Inventory | 1,861 | 1,780 |
Advance to Ibeo | 4,132 | 0 |
Other current assets | 2,306 | 2,283 |
Total current assets | 91,008 | 119,430 |
Property and equipment, net | 6,830 | 3,026 |
Operating lease right-of-use asset | 14,579 | 5,577 |
Restricted cash | 1,418 | 1,092 |
Intangible assets, net | 75 | 115 |
Other assets | 1,086 | 985 |
Total assets | 114,996 | 130,225 |
Current liabilities | ||
Accounts payable | 2,061 | 3,584 |
Accrued liabilities | 2,058 | 1,170 |
Contract liabilities | 4,601 | 5,265 |
Other current liabilities | 839 | 1,181 |
Current portion of long-term debt | 0 | 392 |
Current portion of operating lease liability | 1,846 | 849 |
Current portion of finance lease obligations | 21 | 21 |
Total current liabilities | 11,426 | 12,462 |
Operating lease liability, net of current portion | 13,829 | 4,983 |
Finance lease obligations, net of current portion | 0 | 26 |
Total liabilities | 25,255 | 17,471 |
Commitments and contingencies (Note 14) | ||
Shareholders' equity | ||
Preferred stock, par value $0.001; 25,000 shares authorized; zero and zero shares issued and outstanding, respectively | 0 | 0 |
Common stock, par value $0.001; 210,000 shares authorized; 170,503 and 164,363 shares issued and outstanding at December 31, 2022 and 2021, respectively | 171 | 164 |
Additional paid-in capital | 772,221 | 742,042 |
Accumulated other comprehensive loss | (127) | (19) |
Accumulated deficit | (682,524) | (629,433) |
Total shareholders' equity | 89,741 | 112,754 |
Total liabilities and shareholders' equity | $ 114,996 | $ 130,225 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares shares in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 1 | $ 1 |
Preferred stock, shares authorized | 25,000 | 25,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 1 | $ 1 |
Common stock, shares authorized | 210,000 | 210,000 |
Common stock, shares issued | 170,503 | 170,503 |
Common stock, shares outstanding | 164,363 | 164,363 |
Statements of Operations
Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Total revenue | $ 664 | $ 2,500 | $ 3,090 |
Total cost of revenue | 100 | 2 | 1,398 |
Gross profit | 564 | 2,498 | 1,692 |
Research and development expense | 30,413 | 24,111 | 9,840 |
Sales, marketing, general and administrative expense | 24,041 | 22,256 | 5,917 |
Gain on disposal of fixed assets | 0 | 0 | (450) |
Total operating expenses | 54,454 | 46,367 | 15,307 |
Loss from operations | (53,890) | (43,869) | (13,615) |
Gain on debt extinguishment | 0 | 692 | 0 |
Other income (expense), net | 799 | (23) | (19) |
Net loss | $ (53,091) | $ (43,200) | $ (13,634) |
Net loss per share, basic | $ (0.32) | $ (0.27) | $ (0.1) |
Net loss per share, diluted | $ (0.32) | $ (0.27) | $ (0.1) |
Weighted-average shares outstanding - basic | 165,958 | 160,662 | 139,829 |
Weighted-average shares outstanding - diluted | 165,958 | 160,662 | 139,829 |
Product [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | $ 0 | $ 0 | $ 1,347 |
Cost of Goods and Services | 100 | 2 | 1,394 |
Technology Service [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | 0 | 0 | 25 |
Cost of Goods and Services | 0 | 0 | 4 |
License [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | $ 664 | $ 2,500 | $ 1,718 |
Statement of Comprehensive Loss
Statement of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net loss | $ (53,091) | $ (43,200) | $ (13,634) |
Other comprehensive loss | |||
Unrealized loss on investment securities, available-for-sale | (108) | (19) | 0 |
Comprehensive loss | $ (53,199) | $ (43,219) | $ (13,634) |
Statements of Shareholders' Equ
Statements of Shareholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Receivables from Stockholder [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] |
Beginning balance, value at Dec. 31, 2019 | $ (3,977) | $ 126 | $ 568,496 | $ 0 | $ 0 | $ (572,599) |
Beginning balance, share at Dec. 31, 2019 | 125,803 | |||||
Share-based compensation expense | 1,252 | $ 0 | 1,252 | 0 | 0 | 0 |
Share-based compensation expense, share | 201 | |||||
Sales of common stock, net of issuance costs | 24,368 | $ 26 | 30,477 | (6,135) | 0 | 0 |
Sales of common stock, net of issuance costs, share | 26,229 | |||||
Net loss | (13,634) | $ 0 | 0 | 0 | 0 | (13,634) |
Exercise of options | 1,000 | $ 1 | 999 | 0 | 0 | 0 |
Exercise of options, share | 693 | |||||
Ending balance, share at Dec. 31, 2020 | 152,926 | |||||
Ending balance, value at Dec. 31, 2020 | 9,009 | $ 153 | 601,224 | (6,135) | 0 | (586,233) |
Share-based compensation expense | 15,284 | $ 2 | 15,282 | 0 | 0 | 0 |
Share-based compensation expense, share | 2,365 | |||||
Sales of common stock, net of issuance costs | 129,026 | $ 7 | 122,884 | 6,135 | 0 | 0 |
Sales of common stock, net of issuance costs, share | 7,554 | |||||
Net loss | (43,200) | $ 0 | 0 | 0 | 0 | (43,200) |
Exercise of options | 2,654 | $ 2 | 2,652 | 0 | 0 | 0 |
Exercise of options, share | 1,518 | |||||
Other comprehensive loss | $ (19) | $ 0 | 0 | 0 | (19) | 0 |
Ending balance, share at Dec. 31, 2021 | 164,363 | 164,363 | ||||
Ending balance, value at Dec. 31, 2021 | $ 112,754 | $ 164 | 742,042 | 0 | (19) | (629,433) |
Share-based compensation expense | 15,461 | $ 1 | 15,460 | 0 | 0 | 0 |
Share-based compensation expense, share | 1,294 | |||||
Sales of common stock, net of issuance costs | 13,999 | $ 5 | 13,994 | 0 | 0 | |
Sales of common stock, net of issuance costs, share | 4,321 | |||||
Net loss | (53,091) | $ 0 | 0 | 0 | 0 | (53,091) |
Exercise of options | 726 | $ 1 | 725 | 0 | 0 | 0 |
Exercise of options, share | 525 | |||||
Other comprehensive loss | $ (108) | $ 0 | 0 | 0 | (108) | 0 |
Ending balance, share at Dec. 31, 2022 | 164,363 | 170,503 | ||||
Ending balance, value at Dec. 31, 2022 | $ 89,741 | $ 171 | $ 772,221 | $ 0 | $ (127) | $ (682,524) |
Statements of Cash Flows
Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Net Cash Provided by (Used in) Operating Activities [Abstract] | |||
Net loss | $ (53,091) | $ (43,200) | $ (13,634) |
Adjustments to reconcile net loss to net cash used in operations: | |||
Depreciation and amortization | 2,246 | 1,464 | 963 |
Impairment of property and equipment | 64 | 882 | 0 |
Gain on disposal of property and equipment | 0 | 0 | (450) |
Share-based compensation expense | 15,461 | 15,284 | 1,297 |
Non-cash interest (income) expense | 0 | (10) | 11 |
Inventory write-downs | 87 | 48 | 168 |
Net accretion of premium on short-term investments | 21 | 86 | 0 |
Gain on debt extinguishment | 0 | (692) | 0 |
Change in: | |||
Accounts receivable | 0 | 0 | 1,079 |
Inventory | (168) | (1,828) | 24 |
Other current and non-current assets | (217) | (2,552) | 154 |
Accounts payable | (1,737) | 2,520 | (1,387) |
Accrued liabilities | 888 | 675 | (1,550) |
Deferred revenue | 0 | 0 | (21) |
Contract liabilities and other current liabilities | (293) | (1,319) | (2,073) |
Operating lease liabilities | (1,280) | (762) | (656) |
Net cash used in operating activities | (38,019) | (29,404) | (16,075) |
Cash flows from investing activities | |||
Sales of investment securities | 60,576 | 0 | 0 |
Purchases of investment securities | (90,158) | (32,825) | 0 |
Advance to IBEO | (4,132) | 0 | 0 |
Proceeds from Sale of Property, Plant, and Equipment | 0 | 0 | 525 |
Purchases of property and equipment | (4,359) | (2,493) | (402) |
Net cash provided by (used in) investing activities | (38,073) | (35,318) | 123 |
Net Cash Provided by (Used in) Financing Activities [Abstract] | |||
Principal payments under finance leases | (26) | (28) | (29) |
Proceeds from long-term debt | 0 | 0 | 1,571 |
Principal payments under long-term debt | (392) | (488) | 0 |
Payments received on subscriptions receivable | 0 | 6,135 | 0 |
Proceeds from stock option exercises | 726 | 2,654 | 1,000 |
Net proceeds from issuance of common stock | 13,999 | 122,891 | 24,435 |
Net cash provided by financing activities | 14,307 | 131,164 | 26,977 |
Change in cash, cash equivalents, and restricted cash | (61,785) | 66,442 | 11,025 |
Cash, cash equivalents, and restricted cash at beginning of period | 83,739 | 17,297 | 6,272 |
Cash, cash equivalents, and restricted cash at end of period | 21,954 | 83,739 | 17,297 |
Supplemental schedule of non-cash investing and financing activities | |||
Issuance of common stock for subscriptions receivable | 0 | 0 | 6,135 |
Property and equipment acquired under finance leases | 0 | 0 | 70 |
Lease liabilities from obtaining right-of-use operating asset | 10,184 | 5,097 | 0 |
Non-cash additions to property and equipment | $ 764 | $ 550 | $ 116 |
Reconciliation of Cash Suppleme
Reconciliation of Cash Supplement - USD ($) $ in Thousands | Jan. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | |||||
Cash and cash equivalents | $ 18,500 | $ 20,536 | $ 82,647 | $ 16,862 | |
Restricted cash | 1,418 | 1,092 | 435 | ||
Cash, cash equivalents and restricted cash | $ 21,954 | $ 83,739 | $ 17,297 | $ 6,272 |
1. THE COMPANY AND LIQUIDITY
1. THE COMPANY AND LIQUIDITY | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
1. THE COMPANY AND LIQUIDITY | 1. THE COMPANY AND LIQUIDITY MicroVision, Inc. is developing a lidar sensor to be used in automotive safety and autonomous driving applications. Our lidar sensor uses our pioneering laser beam scanning (LBS) technology. Our LBS technology is based on our patented expertise in systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms and software, and how those elements are packaged into a small form factor. Our lidar sensor also utilizes edge computing and machine intelligence as part of the solutions. Though automotive lidar is our priority now, we have developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. For the past few years, our strategy has been to sell AR displays or components, Interactive Displays, or Consumer Lidars to OEMs and ODMs for incorporation into their products. Currently, our sole customer is Microsoft Corporation. Our arrangement with this customer generates royalty income; however, the volume of sales and resulting royalties from that arrangement are not significant. In the recent past, we shifted our focus to increase the value of the Company by completing development of our 1st Generation LRL module to a level that would be ready to scale in the market. We believe our technology and designs for automotive lidar can be successful in the market, and our solutions will have features and performance that exceed those of competitors and will provide a sustainable strategic advantage in the market. We have incurred significant losses since inception. We have funded our operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales and licensing activities. Between the effectiveness of the Asset Purchase Agreement, December 1, 2022, and the closing of the acquisition, January 31, 2023, we advanced operating funds to Ibeo totaling approximately EUR 6.6 million or approximately $7.1 million to support its ongoing operations while in insolvency, of which $4.1 million was advanced prior to December 31, 2022 and the remaining amount was advanced during January 2023. These funds included costs incurred by Ibeo to reduce its headcount so that only approximately 250 employees would transfer to MicroVision upon the closing of the acquisition. The costs related to the headcount reductions will be reimbursed to MicroVision by way of deduction from the purchase price per the Asset Purchase Agreement. In addition, at closing, MicroVision paid EUR 7.0 million or approximately $7.6 million to Ibeo and EUR 3.0 million or approximately $3.3 million to an escrow account to be available to cover properly established claims by MicroVision. We expect to make the remaining final payment of the purchase price, net of deductions, during the second quarter of 2023. As of January 31, 2023, we had $18.5 million in cash and cash equivalents and $59.2 million in investment securities after making the payments to Ibeo as described above, but excluding the expected impact of the noted final payment that we expect to make in the second quarter. Based on our current operating plan for 2023 and beyond, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months. |
2. SUMMARY OF SIGNIFICANT ACCOU
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from our estimates. We have identified the following areas where estimates and assumptions have been made in preparing the financial statements: revenue recognition, inventory valuation, valuation of share-based payments, income taxes, depreciable lives assessment and related disclosure of contingent assets and liabilities. Cash and cash equivalents and fair value of financial instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy, and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. We use market data, assumptions and risks we believe market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. Our financial instruments include cash and cash equivalents, investment securities, accounts receivable, accounts payable and accrued liabilities. The carrying value of our financial instruments approximates fair value due to their short maturities. Our cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts. Our short-term investment securities are primarily debt securities. The Company has classified its entire investment portfolio as available-for-sale. Available-for-sale Inventory Inventory consists of raw materials, work in process and finished goods assemblies. Inventory is computed using the first-in, first-out (FIFO) method and is stated at the lower of cost and net realizable value. Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. Inventory that will not be consumed through the normal course of business during the next twelve months is classified as “other assets” on the balance sheet. Intangible assets Our intangible assets consist exclusively of purchased patents. The patents are amortized using the straight-line method over their estimated period of benefit, ranging from one to seventeen years. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for our intangible assets is based on the difference between the fair value of the asset and its carrying value. Property and equipment Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets (two to five years) using the straight-line method. Our property and equipment may include assets related to future product lines. As our production needs change, we periodically assess the remaining estimated useful life of our production equipment. If necessary, we adjust the depreciation on our production equipment to reflect the remaining estimated useful life. Leasehold improvements are depreciated over the shorter of estimated useful lives or the lease term. Costs for repairs and maintenance are charged to expense as incurred and expenditures for major improvements are capitalized at cost. Gains or losses on the disposition of assets are reflected in the income statements at the time of disposal. Restricted cash As of December 31, 2022 and 2021, restricted cash was in money market savings accounts and serves as collateral for irrevocable letters of credit related to our facility lease agreements. The restricted cash balance at December 31, 2022 includes $657,000 related to a letter of credit that was issued in connection with a lease agreement entered into in September 2021 for our company headquarters in Redmond, Washington. The new lease commenced on December 1, 2022, and the required balance of the letter credit periodically decreases over the term of the 120-month 120-month Leases We determine if an arrangement is a lease at inception. On our balance sheet, our office lease is included in Operating lease right-of-use ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For leases that do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and non-lease Revenue recognition The following is a description of principal activities from which we generate revenue. Revenues We evaluate contracts based on the 5-step A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard. The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method. The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part. Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time. Product revenue We sell our products to customers under a contract or by purchase order. We consider the sale of each individual item to be one performance obligation. The transaction price is generally either at stated product price per quantity or at a fixed amount at contract inception. Revenue is recognized under Topic 606 when the product is shipped to the customer because control passes to the customer at the point of shipment. Our product sales generally include acceptance provisions, however, because we generally can objectively determine that we have met agreed-upon customer specifications prior to shipment, control of the item passes at the time of shipment. License and royalty revenue We recognize revenue on upfront license fees at a point in time if the nature of the license granted is a right-to-use right-to-access Contract revenue Our contract revenue in a particular period is dependent upon when we enter into a contract, the value of the contracts we have entered into, and the availability of technical resources to perform work on the contracts. We recognize contract revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) occur over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. In contracts that include significant customer acceptance provisions, we recognize revenue only upon acceptance of the deliverable(s). We identify each performance obligation in our development contracts at contract inception. The contracts generally include product development and customization specified by the customer. In contracts with multiple performance obligations, we identify each performance obligation and evaluate whether the performance obligations are distinct within the context of the contract. Performance obligations that are not distinct at contract inception are combined. Our development contracts are primarily fixed-fee Cost of product revenue Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged to us by our contract manufacturers in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with operating our manufacturing capabilities and capacity. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based on the proportion of indirect labor which supported production activities. The cost of product revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of manufacturing overhead expense and the volume of direct material purchased. Cost of contract revenue Cost of contract revenue includes both the direct and allocated indirect costs of performing on contracts and producing prototype units and evaluation kits based on our PicoP ® Our overhead, which includes the costs of procuring, inspecting and storing material, and facility and depreciation costs, is allocated to inventory, cost of product revenue, cost of contract revenue, and research and development expense based on the level of effort supporting production or research and development activity. Concentration of credit risk and major customers and suppliers Concentration of credit risk Financial instruments that potentially subject us to a concentration of credit risk are primarily cash equivalents and accounts receivable. We typically do not require collateral from our customers. As of December 31, 2022, our cash and cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts. Concentration of major customers and suppliers In 2022 one customer, Microsoft Corporation, accounted for $664,000 in revenue, representing 100% of our total revenue. In 2021, the same customer accounted for $2.5 million in revenue, representing 100% of our total revenue. In 2020, the same customer accounted for $3.0 million in revenue, representing 97% of our total revenue. Typically, a significant concentration of our components and the products we have sold are manufactured and obtained from single or limited-source suppliers. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject us to risks and uncertainties including, but not limited to, increased cost of sales, possible loss of revenues, or significant delays in product development or product deliveries, any of which could adversely affect our financial condition and operating results. Income taxes Deferred tax assets and liabilities are recorded for differences between the financial statement and tax bases Net loss per share Basic net loss per share is calculated using the weighted-average number of common shares outstanding during the periods. Net loss per share, assuming dilution, is calculated using the weighted-average number of common shares outstanding and the dilutive effect of all potentially dilutive securities, including common stock equivalents and convertible securities. Net loss per share, assuming dilution, is equal to basic net loss per share because the effect of dilutive securities outstanding during the periods, including options and warrants computed using the treasury stock method, is anti-dilutive. The components of basic and diluted net loss per share were as follows (in thousands, except loss per share data): Year Ended December 31, Numerator: 2022 2021 2020 Net loss available for common shareholders $ (53,091 ) $ (43,200 ) $ (13,634 ) Denominator: Weighted-average common shares outstanding 165,958 160,662 139,829 Net loss per share - basic and diluted $ (0.32 ) $ (0.27 ) $ (0.10 ) During each of the years ended December 31, 2022, 2021 and 2020, we excluded the following securities from net loss per share as the effect of including them would have been anti-dilutive. The shares shown represent the number of shares of common stock which would be issued upon conversion in the respective years shown below (in thousands): Year Ended December 31, 2022 2021 2020 Options outstanding 945 1,533 3,281 Nonvested restricted stock units 8,866 2,625 1,982 9,811 4,158 5,263 Research and development Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. Research and development costs are expensed as incurred. We believe that a substantial level of continuing research and development expense will be required to further develop our technology. Share-based compensation We issue share-based compensation to employees in the form of stock options and restricted stock units (RSUs), and performance stock units (PSUs). We account for the share-based awards by recognizing the fair value of share-based compensation expense on a straight-line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black-Scholes option pricing model. The fair value of RSUs and non-executive The following table summarizes the amount of share-based compensation expense by line item on the Statement of Operations (in thousands): Year Ended December 31, 2022 2021 2020 Research and development expense 6,933 6,125 699 Sales, marketing, general and administrative expense 8,528 9,159 598 $ 15,461 $ 15,284 $ 1,297 Reclassifications Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders’ equity or cash flows, as previously reported. |
3. REVENUE RECOGNITION
3. REVENUE RECOGNITION | 12 Months Ended |
Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue from Contract with Customer [Text Block] | 3. REVENUE RECOGNITION The following is a description of principal activities from which we generate revenue. Revenues are recognized when control of the promised goods or services are transferred to our customers, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We generate all of our revenue from contracts with customers. We evaluate contracts based on the 5-step A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard. The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method. The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part. Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time. Disaggregation of revenue The following table provides information about disaggregated revenue by timing of revenue recognition, (in thousands): Year Ended December 31, 2022 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ — $ 664 $ — $ 664 Product and services transferred over time — — — — Total $ — $ 664 $ — $ 664 Year Ended December 31, 2021 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ — $ 2,500 $ — $ 2,500 Product and services transferred over time — — — — Total $ — $ 2,500 $ — $ 2,500 Year Ended December 31, 2020 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ 1,347 $ 1,718 $ 4 $ 3,069 Product and services transferred over time — — 21 21 Total $ 1,347 $ 1,718 $ 25 $ 3,090 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands): December 31, 2022 2021 2020 Accounts receivable, net $ — $ — $ — Accrued liabilities — — — Deferred revenue — — — Contract liabilities 4,601 5,265 7,765 Under Topic 606, our rights to consideration are presented separately depending on whether those rights are conditional or unconditional. We present our unconditional rights to consideration as “accounts receivable” in our Balance Sheet. Significant changes in the contract assets and the contract liabilities balances during the period are as follows (in thousands, except percentages): December 31, December 31, 2022 2021 $Change % Change Contract assets $ — $ — $ — — Contract liabilities (4,601 ) (5,265 ) 664 12.6 Net contract assets (liabilities) $ (4,601 ) $ (5,265 ) $ 664 12.6 In April 2017, we signed a contract with Microsoft Corporation to develop an LBS display system. Under the agreement, we received an upfront payment of $10.0 million. As of December 31, 2022, we had applied $5.4 million against the contract liability. During the year ended December 31, 2022, we applied $664,000 against the contract liability with this customer. Contract acquisition costs We are required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed. We currently do not pay any commissions upon the signing of a contract; therefore, no commission cost has been incurred as of December 31, 2022. Transaction price allocated to the remaining performance obligations The $10.0 million upfront payment received from our customer as noted above was being recognized as revenue as component sales were transferred to the customer. Under the new arrangement reached in March 2020, the royalties we expect to earn will be applied against the remaining prepayment. Because we do not have information on projected future shipments by our customer, we are not able to estimate the timing of revenue recognition related to the remaining performance obligations. The $4.6 million contract liability is classified as a current liability on our balance sheet. It is likely that recognition of revenue may extend beyond the next twelve months. |
4. INVESTMENT SECURITIES, AVAIL
4. INVESTMENT SECURITIES, AVAILABLE-FOR-SALE AND FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2022 | |
Investments, All Other Investments [Abstract] | |
4. INVESTMENT SECURITIES, AVAILABLE-FOR-SALE AND FAIR VALUE MEASUREMENTS | 4. INVESTMENT SECURITIES, AVAILABLE-FOR-SALE Our investment securities, available-for-sale Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. We use market data, assumptions and risks we believe market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. The hierarchy is summarized below. Level 1 – Quoted prices in active markets for identical assets and liabilities at the measurement date that the reporting entity has the ability to access. Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 – Unobservable inputs for which there is little or no market data, which requires us to develop our own assumptions, which are significant to the measurement of the fair values. The valuation inputs hierarchy classification for assets measured at fair value on a recurring basis are summarized below as of December 31, 2022 and 2021 (in thousands). These tables do not include cash held in our money market savings accounts. As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets Corporate debt securities $ — $ 15,500 $ — $ 15,500 U.S. Treasury securities — 46,673 — 46,673 $ — $ 62,173 $ — $ 62,173 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Corporate debt securities $ — $ 32,720 $ — $ 32,720 $ — $ 32,720 $ — $ 32,720 Our short-term investments are summarized below as of December 31, 2022 and 2021 (in thousands). Investment Cost/ Gross Gross Securities, Amortized Unrealized Unrealized Available- Cost Gains Losses For-Sale As of December 31, 2022 Assets Corporate debt securities $ 15,538 $ — $ (38 ) $ 15,500 U.S. Treasury securities 46,762 2 (91 ) 46,673 $ 62,300 $ 2 $ (129 ) $ 62,173 As of December 31, 2021 Assets Corporate debt securities $ 32,739 $ 3 $ (22 ) $ 32,720 $ 32,739 $ 3 $ (22 ) $ 32,720 The maturities of the investment securities available-for-sale Amortized Gross Gross Estimated As of December 31, 2022 Maturity date Less than one year $ 62,300 $ 2 $ (129 ) $ 62,173 $ 62,300 $ 62,173 As of December 31, 2021 Less than one year $ 32,739 $ 3 $ (22 ) $ 32,720 $ 32,739 $ 32,720 The following table summarizes investments that have been in a continuous unrealized loss position for less than 12 months and those that have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021 (in thousands): Less than Twelve Twelve Months or Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses As of December 31, 2022 Corporate debt securities $ 12,295 $ (38 ) $ — $ — 12,295 (38 ) U.S. Treasury securities 34,530 (91 ) — — 34,530 (91 ) $ 46,825 $ (129 ) $ — $ — $ 46,825 $ (129 ) As of December 31, 2021 Corporate debt securities $ 27,195 $ (22 ) $ — $ — 27,195 (22 ) $ 27,195 $ (22 ) $ — $ — $ 27,195 $ (22 ) |
5. INVENTORY
5. INVENTORY | 12 Months Ended |
Dec. 31, 2022 | |
Inventory Disclosure Abstract | |
5. INVENTORY | 5. INVENTORY Inventory consists of the following (in thousands): December 31, 2022 2021 Raw materials $ 1,556 $ 1,780 Work in process 305 — $ 1,861 $ 1,780 We recorded inventory write-downs of $87,000 in 2022, $48,000 in 2021 and $168,000 in 2020. |
6. ACCRUED LIABILITIES
6. ACCRUED LIABILITIES | 12 Months Ended |
Dec. 31, 2022 | |
Payables And Accruals Abstract | |
6. ACCRUED LIABILITIES | 6. ACCRUED LIABILITIES Accrued liabilities consists of the following (in thousands): December 31, 2022 2021 Bonuses $ 537 $ 43 Payroll and payroll taxes 766 601 Accrued professional fees 378 89 Liabilities to suppliers 130 263 Other 247 174 $ 2,058 $ 1,170 |
7. PROPERTY AND EQUIPMENT
7. PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2022 | |
Property Plant And Equipment Abstract | |
7. PROPERTY AND EQUIPMENT | 7. PROPERTY AND EQUIPMENT Property and equipment consists of the following (in thousands): December 31, 2022 2021 Production equipment $ 6,140 $ 8,224 Leasehold improvements 3,789 913 Computer hardware and software/lab equipment 10,515 7,230 Office furniture and equipment 1,804 1,372 22,248 17,739 Less: Accumulated depreciation (15,418 ) (14,713 ) $ 6,830 $ 3,026 Depreciation expense was $705,000 in 2022, $902,000 in 2021 and $442,000 in 2020. |
8. INTANGIBLE ASSETS
8. INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill And Intangible Assets Disclosure Abstract | |
8. INTANGIBLE ASSETS | 8. INTANGIBLE ASSETS Our intangible assets consist exclusively of technology-based purchased patents. The gross book value of our intangible assets was $951,000 in the years ended December 31, 2022 and 2021, respectively. Amortization expense was $40,000 in 2022, $49,000 in 2021 and $57,000 in 2020. The following table outlines our estimated future amortization expense related to intangible assets held at December 31, 2022 (in thousands): Years Ended December 31, Amount 2023 32 2024 22 2025 14 2026 7 75 |
9. COMMON STOCK
9. COMMON STOCK | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
9. COMMON STOCK | 9. COMMON STOCK In June 2021, we entered into a $140.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we are able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $140.0 million through Craig-Hallum. In 2021, we had issued 4.0 million shares of our common stock for net proceeds of $67.8 million under this ATM agreement. In 2022, we issued 4.3 million shares of our common stock for net proceeds of $14.0 million under this ATM agreement. In January 2023, we issued 5.0 million shares of our common stock for net proceeds of $12.5 million under the agreement. As of February 28, 2023, we have approximately $43.5 In February 2021, we entered into a $50.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $50.0 million through Craig-Hallum. We issued 2.5 million shares of our common stock for net proceeds of $48.8 million under this ATM agreement. No further shares are available for sales under this agreement. In December 2020, we entered into a $13.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, from time to time, at our discretion to offer and sell shares of our common stock having an aggregate value of up to $13.0 million through Craig-Hallum. As of December 31, 2020, we had issued 1.0 million shares for net proceeds of $6.1 million that was received in January 2021. The $6.1 million was classified as subscriptions receivable on our December 31, 2020 balance sheet and is not included in the cash balance as of December 31, 2020. In January 2021, we issued 1.1 million shares of our common stock for net proceeds of $6.6 million under the agreement. In total, we issued 2.1 million shares of our common stock for net proceeds of $12.7 million under this ATM agreement. No further shares are available for sales under this agreement. |
10. SHARE-BASED COMPENSATION
10. SHARE-BASED COMPENSATION | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Of Compensation Related Costs Sharebased Payments Abstract | |
Schedule of Valuation Allowance for Impairment | 10. SHARE-BASED COMPENSATION We use the straight-line attribution method to allocate the fair value of share-based compensation awards over the requisite service period for each award. The valuation of and accounting for share-based awards includes a number of complex and subjective estimates. These estimates include, but are not limited to, the future volatility of our stock price, future stock option exercise behaviors, estimated employee turnover, and award forfeiture rates. Description of Incentive Plan Our 2022 Incentive Plan has 20.0 million shares authorized, which includes 3.5 million shares not issued pursuant to any awards granted under the 2020 Incentive Plan. There were 12.7 million shares available for awards as of December 31, 2022. Options Valuation Methodology and Assumptions We use the Black-Scholes option valuation model to determine the fair value of options granted and use the closing price of our common stock as the fair market value of our stock on that date. We consider historical stock price volatilities, volatilities of similar companies and other factors in determining estimates of future volatilities. We use historical lives, including post-termination exercise behavior, as the basis for estimating expected lives. Risk-free rates are based on the U.S. Treasury Yield Curve, as published by the U.S. Treasury. The following table summarizes the weighted-average valuation assumptions and weighted-average grant date fair value of options granted during the periods shown below: Year Ended December 31, Assumptions (weighted-average) 2022 2021 2020 Volatility — 120 % 111 % Expected term (in years) — 4.0 4.0 Risk-free rate — 0.9 % 0.3 % Expected dividends — 0.0 % 0.0 % Pre-vest — 8.5 % 8.5 % Grant date fair value of options granted $ — $ 11.72 $ 1.20 Options Activity and Positions The following table summarizes activity and positions with respect to options for the periods shown below (in thousands): Weighted-average remaining Aggregate Weighted-average contractual intrinsic Options Shares exercise price term (in years) value Outstanding as of December 31, 2019 5,104 1.66 7.4 $ 122 Granted 68 1.60 Exercised (693 ) 1.44 Forfeited or expired (1,198 ) 2.20 Outstanding as of December 31, 2020 3,281 1.51 6.6 $ 12,784 Granted 8 14.04 Exercised (1,519 ) 1.75 Forfeited or expired (237 ) 1.23 Outstanding as of December 31, 2021 1,533 1.37 5.6 $ 5,645 Granted — — Exercised (525 ) 1.38 Forfeited or expired (63 ) 3.00 Outstanding as of December 31, 2022 945 $ 1.26 5.7 $ 1,137 Vested and expected to vest as of December 31, 2022 945 $ 1.26 5.7 $ 1,136 Exercisable as of December 31, 2022 941 $ 1.26 5.7 $ 1,129 The total grant date fair value of options vested during the years ended December 31, 2022, 2021 and 2020 was $115,000, $508,000 and $604,000, respectively. As of December 31, 2022, our unrecognized share-based compensation was $1,000 related to options, which we plan to expense over the next 1.2 years. Restricted stock activity and positions The following table summarizes activity and positions with respect to RSUs and PSUs for the three years ended December 31, 2022 (in thousands): Weighted-average Shares price Unvested as of December 31, 2019 1,215 0.40 Granted 1,462 1.08 Vested (219 ) 0.88 Forfeited (475 ) 0.77 Unvested as of December 31, 2020 1,983 0.76 Granted 4,179 12.92 Vested (2,380 ) 3.11 Forfeited (1,157 ) 11.97 Unvested as of December 31, 2021 2,625 13.05 Granted 9,180 2.46 Vested (1,391 ) 9.16 Forfeited (1,548 ) 6.42 Unvested as of December 31, 2022 8,866 $ 3.85 In June 2022, we issued 6.0 million PSUs to our executive officers. The PSUs are subject to the achievement of performance goals and time-based vesting. The PSUs will become eligible to vest if the closing price of our common stock reaches or exceeds specified price thresholds for at least 20 consecutive trading days during the performance period through December 31, 2025. If the performance goals are met, the portion of the PSUs deemed earned will become subject to time-based vesting in equal quarterly installments over two years starting from the date on which the goal is achieved. These PSUs were valued using a Monte Carlo simulation model using the following inputs: stock price, volatility, and risk-free interest rates. In 2022, we issued 2.4 million PSUs to non-executive re-issued In 2022, we issued 570,000 time-based RSUs to non-executive In 2021, an equity award was granted to the Chief Executive Officer in the form of 1.2 million restricted stock units. These shares were valued based on the closing price of our common stock on the dates of grant. On the date of grant, 300,000 shares vested immediately, 300,000 vested in April 2022 and subsequent grants of 300,000 RSUs will be made on an annual basis in each of April 2023 and April 2024. In 2021, we issued 1.5 million shares of performance stock units to non-executive one-eighth In 2021, we issued 1.1 million RSUs to non-executive As of December 31, 2022, our unrecognized share-based compensation related to RSUs was $13.1 million, which we plan to expense over the next 1.6 years, our unrecognized share-based compensation related to executive PSUs was $7.9 million, which we plan to expense over the next 2.7 years, and our unrecognized share-based compensation related to the non-executive |
11. LEASES
11. LEASES | 12 Months Ended |
Dec. 31, 2022 | |
Leases [Abstract] | |
Lessee, Operating Leases [Text Block] | 11. LEASES We lease our office space and certain equipment under finance and operating leases. Our leases have remaining lease terms of one month to ten years. Our office lease agreement includes both lease and non-lease In September 2021, we entered into an office lease with Redmond East Office Park LLC, a Washington limited liability company, pursuant to which we will lease approximately 16,681 square feet of space located in Redmond, Washington that we will use primarily for general office space and product testing. The lease provides for an initial term of 128 months that commenced November 1, 2021. Pursuant to the lease, annual base rent will be approximately $ 500,000 3.0 ten-year 6.4 In September 2021, we entered into a second office lease with Redmond East Office Park LLC, pursuant to which we will lease approximately 36,062 square feet of space located in Redmond, Washington that we will use primarily for general office and lab space. The lease provides for an initial term of 120 months and commenced on December 1, 2022. Pursuant to the lease, annual base rent will be approximately $ 1.1 ten-year 13.0 right-of-use In connection with the effectiveness of the second lease with Redmond East Office Park, we amended our current office lease and will have access until January 31, 2023 to coincide with our move into the new 36,062 square feet of space. In April 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,533 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced May 1, 2022. Pursuant to the lease, annual base rent is approximately $ 76,000 380,000 In September 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,810 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced November 15, 2022. Pursuant to the lease, annual base rent is approximately $92,000 per year. The total minimum lease payments related to this lease is approximately $461,000. The components of lease expense were as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Operating lease expense $ 1,501 $ 513 $ 464 Finance lease expense: Amortization of leased assets 26 30 26 Interest on lease liabilities 2 3 3 Total finance lease expense 28 33 29 Total lease expense $ 1,529 $ 546 $ 493 Supplemental cash flow information related to leases was as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,280 $ 762 $ 656 Operating cash flows from finance leases 2 3 3 Financing cash flows from finance leases 26 28 29 Right-of-use Operating leases $ 10,184 $ 5,322 $ — Supplemental balance sheet information related to leases was as follows: December 31, (in thousands) 2022 2021 Operating leases Operating lease right-of-use $ 14,579 $ 5,577 Current portion of operating lease liability 1,846 849 Operating lease liability, net of current portion 13,829 4,983 Total operating lease liabilities $ 15,675 $ 5,832 Finance leases Property and equipment, at cost $ 112 $ 112 Accumulated depreciation (80 ) (56 ) Property and equipment, net $ 32 $ 56 Current portion of finance lease obligations $ 21 $ 21 Finance lease obligations, net of current portion — 26 Total finance lease liabilities $ 21 $ 47 Weighted Average Remaining Lease Term Operating leases 13.1 years 9.5 years Finance leases 0.5 years 1.2 years Weighted Average Discount Rate Operating leases 9.0 % 2.5 % Finance leases 6.3 % 6.3 % As of December 31, 2022, maturities of lease liabilities were as follows: (in thousands) Operating Finance Years Ended December 31, leases leases 2023 1,904 22 2024 1,896 — 2025 1,947 — 2026 2,000 — Thereafter 11,642 — Total minimum lease payments 19,389 22 Less: amount representing interest (3,714 ) (1 ) Present value of lease liabilities $ 15,675 $ 21 |
12. COMMITMENTS AND CONTINGENCI
12. COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
12. COMMITMENTS AND CONTINGENCIES | 12. COMMITMENTS AND CONTINGENCIES Litigation We are subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently party to any legal proceedings that management believes are reasonably possible to have a material adverse effect on our financial position, results of operations or cash flows. |
13. INCOME TAXES
13. INCOME TAXES | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure Abstract | |
13. INCOME TAXES | 13. INCOME TAXES No provision for income taxes has been recorded for 2022, 2021 and 2020 due to the valuation allowances placed against the net operating losses and deferred tax assets arising during such periods. A valuation allowance has been recorded for all deferred tax assets. Based on our history of losses since inception, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets. The effective tax rate of our provision (benefit) for income taxes differs from the Federal statutory rate as follows: Year Ended December 31, 2022 2021 2020 Statutory rate 21.0 % 21.0 % 21.0 % Compensation related (0.5 )% (8.2 )% 0.0 % Share-based compensation (2.2 )% 25.1 % 0.0 % Net operating loss expiration (9.0 )% (16.2 )% (47.5 )% Tax credits 1.5 % 1.4 % 2.2 % Change in valuation allowance (10.8 )% (23.1 )% 24.3 % Total 0.0 % 0.0 % 0.0 % Deferred tax assets are summarized as follows (in thousands): December 31, 2022 2021 Deferred tax assets Reserves $ 651 $ 634 Net operating loss carryforwards 92,469 90,593 R&D credit carryforwards 9,628 8,984 Depreciation/amortization deferred 19,787 17,417 Operating lease liabilities 3,292 1,222 Other 7,360 6,701 Total deferred tax assets 133,187 125,551 Deferred tax liabilities: Operating lease right-of-use (3,062 ) (1,171 ) Total deferred tax liabilities (3,062 ) (1,171 ) Net valuation allowances (130,125 ) (124,380 ) Deferred tax assets $ — $ — At December 31, 2022, we have net operating loss carryforwards of approximately $ 440.3 9.6 22.0 171,000 2023 2042 Certain net operating losses arise from the deductibility for tax purposes of compensation under nonqualified stock options equal to the difference between the fair value of the stock on the date of exercise and the exercise price of the options. For financial reporting purposes, the tax effect of this deduction, when recognized, is accounted for as an income tax benefit. In certain circumstances, as specified in the Internal Revenue Code, a 50% or more ownership change by certain combinations of our shareholders during any three year period would result in limitations on our ability to use a portion of our net operating loss carryforwards. We had no unrecognized tax benefits at December 31, 2022 or 2021. We recognize interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022, 2021 and 2020 we recognized no interest or penalties. We file income tax returns in the U.S. federal jurisdiction and Oregon. Due to our operating loss and credit carryforwards, the U.S. federal statute of limitations remains open for 1998 and onward. |
14. RETIREMENT SAVINGS PLAN
14. RETIREMENT SAVINGS PLAN | 12 Months Ended |
Dec. 31, 2022 | |
Postemployment Benefits [Abstract] | |
14. RETIREMENT SAVINGS PLAN | 14. RETIREMENT SAVINGS PLAN We have a retirement savings plan that qualifies under Internal Revenue Code Section 401(k). The plan covers all qualified employees. Contributions to the plan are made at the discretion of our Board of Directors. During the years ended December 31, 2022, 2021 and 2020 we contributed $411,000, $259,000 and $213,000 to the plan, respectively. |
15. QUARTERLY FINANCIAL INFORMA
15. QUARTERLY FINANCIAL INFORMATION (Unaudited) | 12 Months Ended |
Dec. 31, 2022 | |
Quarterly Financial Information Disclosure [Abstract] | |
15. QUARTERLY FINANCIAL INFORMATION (Unaudited) | 15. QUARTERLY FINANCIAL INFORMATION (Unaudited) The following table summarizes our unaudited quarterly financial information for the periods shown below (in thousands, except per share data): Fiscal Year 2022 December 31, September 30, June 30, March 31, Revenue $ — $ — $ 314 $ 350 Gross profit (33 ) (45 ) 296 346 Net loss (13,475 ) (12,851 ) (13,597 ) (13,168 ) Net loss per share, basic and diluted (0.08 ) (0.08 ) (0.08 ) (0.08 ) Fiscal Year 2021 December 31, September 30, June 30, March 31, Revenue $ 557 $ 718 $ 746 $ 479 Gross profit 509 728 777 484 Net loss (12,625 ) (9,382 ) (14,962 ) (6,231 ) Net loss per share, basic and diluted (0.08 ) (0.06 ) (0.09 ) (0.04 ) Fiscal Year 2020 December 31, September 30, June 30, March 31, Revenue $ 395 $ 639 $ 587 $ 1,469 Gross profit 395 639 588 70 Net loss (3,570 ) (2,826 ) (2,304 ) (4,934 ) Net loss per share, basic and diluted (0.02 ) (0.02 ) (0.02 ) (0.04 ) |
16. SUBSEQUENT EVENT
16. SUBSEQUENT EVENT | 12 Months Ended |
Dec. 31, 2022 | |
Subsequent Events [Abstract] | |
16. SUBSEQUENT EVENT | 16. SUBSEQUENT EVENT On December 1, 2022, MicroVision GmbH, a company organized under the laws of The Federal Republic of Germany and wholly owned subsidiary of MicroVision, Inc., entered into an Asset Purchase Agreement with Ibeo Automotive Systems GmbH, a company organized under the laws of The Federal Republic of Germany, pursuant to which MicroVision has agreed to acquire from Ibeo certain assets related to Ibeo’s lidar sensor business. Ibeo Automotive Systems GmbH also operates in the ADAS industry providing Lidar based solutions to its customers. Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the purchase price MicroVision agreed to pay to Ibeo is EUR 15.0 million or approximately $16.1 million, subject to potential reduction on the terms set forth in the Asset Purchase Agreement. MicroVision has also advanced operating funds to Ibeo during the pre-Closing On January 31, 2023, the acquisition of certain assets of Ibeo was completed. Through the closing date, Microvision has advanced operating funds to Ibeo totaling EUR 6.6 million or approximately $7.1 million for its ongoing operations, of which $4.1 million was advanced prior to December 31, 2022 and the remaining amount was advanced during January 2023. These operating funds also included costs related to headcount reductions carried out by Ibeo management, decreasing the number of employees to transfer in connection with the acquisition to approximately 250 employees. These headcount reduction costs will be reimbursed to MicroVision by way of deduction from the purchase price in accordance with the Asset Purchase Agreement. In addition, upon closing, MicroVision has made payments of EUR 7.0 million or approximately $7.6 million to Ibeo and EUR 3.0 million or approximately $3.3 million to an escrow account towards the purchase price. We expect to make the remaining final payment in Q2 2023 net of all such costs that will be reimbursed to MicroVision per the Asset Purchase Agreement. |
Schedule II
Schedule II | 12 Months Ended |
Dec. 31, 2022 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II | Schedule II MicroVision, Inc. Valuation and Qualifying Accounts and Reserves Schedule (In thousands) Additions Balance at Charges Charges Balance beginning of to costs and to other at end of Year Ended December 31, fiscal period expenses accounts Deductions fiscal period 2020 Tax valuation allowance $ 117,725 $ — $ — $ (3,318 ) $ 114,407 2021 Tax valuation allowance $ 114,407 $ 9,973 $ — $ — $ 124,380 2022 Tax valuation allowance $ 124,380 $ 5,745 $ — $ — $ 130,125 |
2. SUMMARY OF SIGNIFICANT ACC_2
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from our estimates. We have identified the following areas where estimates and assumptions have been made in preparing the financial statements: revenue recognition, inventory valuation, valuation of share-based payments, income taxes, depreciable lives assessment and related disclosure of contingent assets and liabilities. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and cash equivalents and fair value of financial instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy, and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. We use market data, assumptions and risks we believe market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. Our financial instruments include cash and cash equivalents, investment securities, accounts receivable, accounts payable and accrued liabilities. The carrying value of our financial instruments approximates fair value due to their short maturities. Our cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts. Our short-term investment securities are primarily debt securities. The Company has classified its entire investment portfolio as available-for-sale. Available-for-sale |
Inventory | Inventory Inventory consists of raw materials, work in process and finished goods assemblies. Inventory is computed using the first-in, first-out (FIFO) method and is stated at the lower of cost and net realizable value. Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. Inventory that will not be consumed through the normal course of business during the next twelve months is classified as “other assets” on the balance sheet. |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intangible assets Our intangible assets consist exclusively of purchased patents. The patents are amortized using the straight-line method over their estimated period of benefit, ranging from one to seventeen years. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for our intangible assets is based on the difference between the fair value of the asset and its carrying value. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and equipment Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets (two to five years) using the straight-line method. Our property and equipment may include assets related to future product lines. As our production needs change, we periodically assess the remaining estimated useful life of our production equipment. If necessary, we adjust the depreciation on our production equipment to reflect the remaining estimated useful life. Leasehold improvements are depreciated over the shorter of estimated useful lives or the lease term. Costs for repairs and maintenance are charged to expense as incurred and expenditures for major improvements are capitalized at cost. Gains or losses on the disposition of assets are reflected in the income statements at the time of disposal. |
Restricted cash | Restricted cash As of December 31, 2022 and 2021, restricted cash was in money market savings accounts and serves as collateral for irrevocable letters of credit related to our facility lease agreements. The restricted cash balance at December 31, 2022 includes $657,000 related to a letter of credit that was issued in connection with a lease agreement entered into in September 2021 for our company headquarters in Redmond, Washington. The new lease commenced on December 1, 2022, and the required balance of the letter credit periodically decreases over the term of the 120-month 120-month |
Lessee, Leases [Policy Text Block] | Leases We determine if an arrangement is a lease at inception. On our balance sheet, our office lease is included in Operating lease right-of-use ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For leases that do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and non-lease |
Long-Duration Contracts Revenue Recognition, Policy [Policy Text Block] | Revenue recognition The following is a description of principal activities from which we generate revenue. Revenues We evaluate contracts based on the 5-step A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard. The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method. The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part. Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time. |
Product revenue | Product revenue We sell our products to customers under a contract or by purchase order. We consider the sale of each individual item to be one performance obligation. The transaction price is generally either at stated product price per quantity or at a fixed amount at contract inception. Revenue is recognized under Topic 606 when the product is shipped to the customer because control passes to the customer at the point of shipment. Our product sales generally include acceptance provisions, however, because we generally can objectively determine that we have met agreed-upon customer specifications prior to shipment, control of the item passes at the time of shipment. |
License and royalty revenue | License and royalty revenue We recognize revenue on upfront license fees at a point in time if the nature of the license granted is a right-to-use right-to-access |
Contract revenue | Contract revenue Our contract revenue in a particular period is dependent upon when we enter into a contract, the value of the contracts we have entered into, and the availability of technical resources to perform work on the contracts. We recognize contract revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) occur over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. In contracts that include significant customer acceptance provisions, we recognize revenue only upon acceptance of the deliverable(s). We identify each performance obligation in our development contracts at contract inception. The contracts generally include product development and customization specified by the customer. In contracts with multiple performance obligations, we identify each performance obligation and evaluate whether the performance obligations are distinct within the context of the contract. Performance obligations that are not distinct at contract inception are combined. Our development contracts are primarily fixed-fee |
Cost of Goods and Service [Policy Text Block] | Cost of product revenue Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged to us by our contract manufacturers in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with operating our manufacturing capabilities and capacity. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based on the proportion of indirect labor which supported production activities. The cost of product revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of manufacturing overhead expense and the volume of direct material purchased. |
Cost of contract revenue | Cost of contract revenue Cost of contract revenue includes both the direct and allocated indirect costs of performing on contracts and producing prototype units and evaluation kits based on our PicoP ® Our overhead, which includes the costs of procuring, inspecting and storing material, and facility and depreciation costs, is allocated to inventory, cost of product revenue, cost of contract revenue, and research and development expense based on the level of effort supporting production or research and development activity. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of credit risk and major customers and suppliers Concentration of credit risk Financial instruments that potentially subject us to a concentration of credit risk are primarily cash equivalents and accounts receivable. We typically do not require collateral from our customers. As of December 31, 2022, our cash and cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts. Concentration of major customers and suppliers In 2022 one customer, Microsoft Corporation, accounted for $664,000 in revenue, representing 100% of our total revenue. In 2021, the same customer accounted for $2.5 million in revenue, representing 100% of our total revenue. In 2020, the same customer accounted for $3.0 million in revenue, representing 97% of our total revenue. Typically, a significant concentration of our components and the products we have sold are manufactured and obtained from single or limited-source suppliers. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject us to risks and uncertainties including, but not limited to, increased cost of sales, possible loss of revenues, or significant delays in product development or product deliveries, any of which could adversely affect our financial condition and operating results. |
Income Tax, Policy [Policy Text Block] | Income taxes Deferred tax assets and liabilities are recorded for differences between the financial statement and tax bases |
Earnings Per Share, Policy [Policy Text Block] | Net loss per share Basic net loss per share is calculated using the weighted-average number of common shares outstanding during the periods. Net loss per share, assuming dilution, is calculated using the weighted-average number of common shares outstanding and the dilutive effect of all potentially dilutive securities, including common stock equivalents and convertible securities. Net loss per share, assuming dilution, is equal to basic net loss per share because the effect of dilutive securities outstanding during the periods, including options and warrants computed using the treasury stock method, is anti-dilutive. The components of basic and diluted net loss per share were as follows (in thousands, except loss per share data): Year Ended December 31, Numerator: 2022 2021 2020 Net loss available for common shareholders $ (53,091 ) $ (43,200 ) $ (13,634 ) Denominator: Weighted-average common shares outstanding 165,958 160,662 139,829 Net loss per share - basic and diluted $ (0.32 ) $ (0.27 ) $ (0.10 ) During each of the years ended December 31, 2022, 2021 and 2020, we excluded the following securities from net loss per share as the effect of including them would have been anti-dilutive. The shares shown represent the number of shares of common stock which would be issued upon conversion in the respective years shown below (in thousands): Year Ended December 31, 2022 2021 2020 Options outstanding 945 1,533 3,281 Nonvested restricted stock units 8,866 2,625 1,982 9,811 4,158 5,263 |
Research and Development Expense, Policy [Policy Text Block] | Research and development Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. Research and development costs are expensed as incurred. We believe that a substantial level of continuing research and development expense will be required to further develop our technology. |
Share-Based Payment Arrangement [Policy Text Block] | Share-based compensation We issue share-based compensation to employees in the form of stock options and restricted stock units (RSUs), and performance stock units (PSUs). We account for the share-based awards by recognizing the fair value of share-based compensation expense on a straight-line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black-Scholes option pricing model. The fair value of RSUs and non-executive The following table summarizes the amount of share-based compensation expense by line item on the Statement of Operations (in thousands): Year Ended December 31, 2022 2021 2020 Research and development expense 6,933 6,125 699 Sales, marketing, general and administrative expense 8,528 9,159 598 $ 15,461 $ 15,284 $ 1,297 |
Comparability of Prior Year Financial Data, Policy [Policy Text Block] | Reclassifications Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders’ equity or cash flows, as previously reported. |
2. SUMMARY OF SIGNIFICANT ACC_3
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The components of basic and diluted net loss per share were as follows (in thousands, except loss per share data): Year Ended December 31, Numerator: 2022 2021 2020 Net loss available for common shareholders $ (53,091 ) $ (43,200 ) $ (13,634 ) Denominator: Weighted-average common shares outstanding 165,958 160,662 139,829 Net loss per share - basic and diluted $ (0.32 ) $ (0.27 ) $ (0.10 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | During each of the years ended December 31, 2022, 2021 and 2020, we excluded the following securities from net loss per share as the effect of including them would have been anti-dilutive. The shares shown represent the number of shares of common stock which would be issued upon conversion in the respective years shown below (in thousands): Year Ended December 31, 2022 2021 2020 Options outstanding 945 1,533 3,281 Nonvested restricted stock units 8,866 2,625 1,982 9,811 4,158 5,263 |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | The following table summarizes the amount of share-based compensation expense by line item on the Statement of Operations (in thousands): Year Ended December 31, 2022 2021 2020 Research and development expense 6,933 6,125 699 Sales, marketing, general and administrative expense 8,528 9,159 598 $ 15,461 $ 15,284 $ 1,297 |
3. REVENUE RECOGNITION (Tables)
3. REVENUE RECOGNITION (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The following table provides information about disaggregated revenue by timing of revenue recognition, (in thousands): Year Ended December 31, 2022 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ — $ 664 $ — $ 664 Product and services transferred over time — — — — Total $ — $ 664 $ — $ 664 Year Ended December 31, 2021 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ — $ 2,500 $ — $ 2,500 Product and services transferred over time — — — — Total $ — $ 2,500 $ — $ 2,500 Year Ended December 31, 2020 License and Product royalty Contract revenue revenue revenue Total Timing of revenue recognition: Products transferred at a point in time $ 1,347 $ 1,718 $ 4 $ 3,069 Product and services transferred over time — — 21 21 Total $ 1,347 $ 1,718 $ 25 $ 3,090 |
Significant Changes in Contract Assets and Contract Liabilities | The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands): December 31, 2022 2021 2020 Accounts receivable, net $ — $ — $ — Accrued liabilities — — — Deferred revenue — — — Contract liabilities 4,601 5,265 7,765 Under Topic 606, our rights to consideration are presented separately depending on whether those rights are conditional or unconditional. We present our unconditional rights to consideration as “accounts receivable” in our Balance Sheet. Significant changes in the contract assets and the contract liabilities balances during the period are as follows (in thousands, except percentages): December 31, December 31, 2022 2021 $Change % Change Contract assets $ — $ — $ — — Contract liabilities (4,601 ) (5,265 ) 664 12.6 Net contract assets (liabilities) $ (4,601 ) $ (5,265 ) $ 664 12.6 |
4. INVESTMENT SECURITIES, AVA_2
4. INVESTMENT SECURITIES, AVAILABLE-FOR-SALE AND FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Investments, All Other Investments [Abstract] | |
Schedule of Fair Value Hierarchy Assets and Liabilities | The valuation inputs hierarchy classification for assets measured at fair value on a recurring basis are summarized below as of December 31, 2022 and 2021 (in thousands). These tables do not include cash held in our money market savings accounts. As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets Corporate debt securities $ — $ 15,500 $ — $ 15,500 U.S. Treasury securities — 46,673 — 46,673 $ — $ 62,173 $ — $ 62,173 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Corporate debt securities $ — $ 32,720 $ — $ 32,720 $ — $ 32,720 $ — $ 32,720 |
Schedule of Unrealized Gain or Loss on Short-term Investments | Our short-term investments are summarized below as of December 31, 2022 and 2021 (in thousands). Investment Cost/ Gross Gross Securities, Amortized Unrealized Unrealized Available- Cost Gains Losses For-Sale As of December 31, 2022 Assets Corporate debt securities $ 15,538 $ — $ (38 ) $ 15,500 U.S. Treasury securities 46,762 2 (91 ) 46,673 $ 62,300 $ 2 $ (129 ) $ 62,173 As of December 31, 2021 Assets Corporate debt securities $ 32,739 $ 3 $ (22 ) $ 32,720 $ 32,739 $ 3 $ (22 ) $ 32,720 |
+Maturity Date of Available-for-sale Securities | The maturities of the investment securities available-for-sale Amortized Gross Gross Estimated As of December 31, 2022 Maturity date Less than one year $ 62,300 $ 2 $ (129 ) $ 62,173 $ 62,300 $ 62,173 As of December 31, 2021 Less than one year $ 32,739 $ 3 $ (22 ) $ 32,720 $ 32,739 $ 32,720 |
Schedule of Unrealized Loss on Investment Securities | The following table summarizes investments that have been in a continuous unrealized loss position for less than 12 months and those that have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021 (in thousands): Less than Twelve Twelve Months or Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses As of December 31, 2022 Corporate debt securities $ 12,295 $ (38 ) $ — $ — 12,295 (38 ) U.S. Treasury securities 34,530 (91 ) — — 34,530 (91 ) $ 46,825 $ (129 ) $ — $ — $ 46,825 $ (129 ) As of December 31, 2021 Corporate debt securities $ 27,195 $ (22 ) $ — $ — 27,195 (22 ) $ 27,195 $ (22 ) $ — $ — $ 27,195 $ (22 ) |
5. INVENTORY (Tables)
5. INVENTORY (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Inventory Disclosure Abstract | |
Components of Inventory | Inventory consists of the following (in thousands): December 31, 2022 2021 Raw materials $ 1,556 $ 1,780 Work in process 305 — $ 1,861 $ 1,780 |
6. ACCRUED LIABILITIES (Tables)
6. ACCRUED LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Payables And Accruals Abstract | |
Table of Accrued Liabilities | Accrued liabilities consists of the following (in thousands): December 31, 2022 2021 Bonuses $ 537 $ 43 Payroll and payroll taxes 766 601 Accrued professional fees 378 89 Liabilities to suppliers 130 263 Other 247 174 $ 2,058 $ 1,170 |
7. PROPERTY AND EQUIPMENT (Tabl
7. PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Property Plant And Equipment Abstract | |
Components of Property, Plant and Equipment | Property and equipment consists of the following (in thousands): December 31, 2022 2021 Production equipment $ 6,140 $ 8,224 Leasehold improvements 3,789 913 Computer hardware and software/lab equipment 10,515 7,230 Office furniture and equipment 1,804 1,372 22,248 17,739 Less: Accumulated depreciation (15,418 ) (14,713 ) $ 6,830 $ 3,026 |
8. INTANGIBLE ASSETS (Tables)
8. INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill And Intangible Assets Disclosure Abstract | |
Estimated Future Amortization Expense Related to Intangible Assets | The following table outlines our estimated future amortization expense related to intangible assets held at December 31, 2022 (in thousands): Years Ended December 31, Amount 2023 32 2024 22 2025 14 2026 7 75 |
10. SHARE-BASED COMPENSATION (T
10. SHARE-BASED COMPENSATION (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Of Compensation Related Costs Sharebased Payments Abstract | |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The following table summarizes the weighted-average valuation assumptions and weighted-average grant date fair value of options granted during the periods shown below: Year Ended December 31, Assumptions (weighted-average) 2022 2021 2020 Volatility — 120 % 111 % Expected term (in years) — 4.0 4.0 Risk-free rate — 0.9 % 0.3 % Expected dividends — 0.0 % 0.0 % Pre-vest — 8.5 % 8.5 % Grant date fair value of options granted $ — $ 11.72 $ 1.20 |
Schedule of Valuation Assumptions for Stock Options | The following table summarizes activity and positions with respect to options for the periods shown below (in thousands): Weighted-average remaining Aggregate Weighted-average contractual intrinsic Options Shares exercise price term (in years) value Outstanding as of December 31, 2019 5,104 1.66 7.4 $ 122 Granted 68 1.60 Exercised (693 ) 1.44 Forfeited or expired (1,198 ) 2.20 Outstanding as of December 31, 2020 3,281 1.51 6.6 $ 12,784 Granted 8 14.04 Exercised (1,519 ) 1.75 Forfeited or expired (237 ) 1.23 Outstanding as of December 31, 2021 1,533 1.37 5.6 $ 5,645 Granted — — Exercised (525 ) 1.38 Forfeited or expired (63 ) 3.00 Outstanding as of December 31, 2022 945 $ 1.26 5.7 $ 1,137 Vested and expected to vest as of December 31, 2022 945 $ 1.26 5.7 $ 1,136 Exercisable as of December 31, 2022 941 $ 1.26 5.7 $ 1,129 |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | The following table summarizes activity and positions with respect to RSUs and PSUs for the three years ended December 31, 2022 (in thousands): Weighted-average Shares price Unvested as of December 31, 2019 1,215 0.40 Granted 1,462 1.08 Vested (219 ) 0.88 Forfeited (475 ) 0.77 Unvested as of December 31, 2020 1,983 0.76 Granted 4,179 12.92 Vested (2,380 ) 3.11 Forfeited (1,157 ) 11.97 Unvested as of December 31, 2021 2,625 13.05 Granted 9,180 2.46 Vested (1,391 ) 9.16 Forfeited (1,548 ) 6.42 Unvested as of December 31, 2022 8,866 $ 3.85 |
11. LEASES (Tables)
11. LEASES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Leases [Abstract] | |
Lease, Cost [Table Text Block] | The components of lease expense were as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Operating lease expense $ 1,501 $ 513 $ 464 Finance lease expense: Amortization of leased assets 26 30 26 Interest on lease liabilities 2 3 3 Total finance lease expense 28 33 29 Total lease expense $ 1,529 $ 546 $ 493 |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | Supplemental cash flow information related to leases was as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,280 $ 762 $ 656 Operating cash flows from finance leases 2 3 3 Financing cash flows from finance leases 26 28 29 Right-of-use Operating leases $ 10,184 $ 5,322 $ — |
Cash Flow Information Related to Leases | Supplemental balance sheet information related to leases was as follows: December 31, (in thousands) 2022 2021 Operating leases Operating lease right-of-use $ 14,579 $ 5,577 Current portion of operating lease liability 1,846 849 Operating lease liability, net of current portion 13,829 4,983 Total operating lease liabilities $ 15,675 $ 5,832 Finance leases Property and equipment, at cost $ 112 $ 112 Accumulated depreciation (80 ) (56 ) Property and equipment, net $ 32 $ 56 Current portion of finance lease obligations $ 21 $ 21 Finance lease obligations, net of current portion — 26 Total finance lease liabilities $ 21 $ 47 Weighted Average Remaining Lease Term Operating leases 13.1 years 9.5 years Finance leases 0.5 years 1.2 years Weighted Average Discount Rate Operating leases 9.0 % 2.5 % Finance leases 6.3 % 6.3 % |
Contractual Obligation, Fiscal Year Maturity [Table Text Block] | As of December 31, 2022, maturities of lease liabilities were as follows: (in thousands) Operating Finance Years Ended December 31, leases leases 2023 1,904 22 2024 1,896 — 2025 1,947 — 2026 2,000 — Thereafter 11,642 — Total minimum lease payments 19,389 22 Less: amount representing interest (3,714 ) (1 ) Present value of lease liabilities $ 15,675 $ 21 |
13. INCOME TAXES (Tables)
13. INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure Abstract | |
Schedule of Effective Income Tax Rate Reconciliation | The effective tax rate of our provision (benefit) for income taxes differs from the Federal statutory rate as follows: Year Ended December 31, 2022 2021 2020 Statutory rate 21.0 % 21.0 % 21.0 % Compensation related (0.5 )% (8.2 )% 0.0 % Share-based compensation (2.2 )% 25.1 % 0.0 % Net operating loss expiration (9.0 )% (16.2 )% (47.5 )% Tax credits 1.5 % 1.4 % 2.2 % Change in valuation allowance (10.8 )% (23.1 )% 24.3 % Total 0.0 % 0.0 % 0.0 % |
Schedule of Deferred Tax Assets | Deferred tax assets are summarized as follows (in thousands): December 31, 2022 2021 Deferred tax assets Reserves $ 651 $ 634 Net operating loss carryforwards 92,469 90,593 R&D credit carryforwards 9,628 8,984 Depreciation/amortization deferred 19,787 17,417 Operating lease liabilities 3,292 1,222 Other 7,360 6,701 Total deferred tax assets 133,187 125,551 Deferred tax liabilities: Operating lease right-of-use (3,062 ) (1,171 ) Total deferred tax liabilities (3,062 ) (1,171 ) Net valuation allowances (130,125 ) (124,380 ) Deferred tax assets $ — $ — |
15. QUARTERLY FINANCIAL INFOR_2
15. QUARTERLY FINANCIAL INFORMATION (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Information | The following table summarizes our unaudited quarterly financial information for the periods shown below (in thousands, except per share data): Fiscal Year 2022 December 31, September 30, June 30, March 31, Revenue $ — $ — $ 314 $ 350 Gross profit (33 ) (45 ) 296 346 Net loss (13,475 ) (12,851 ) (13,597 ) (13,168 ) Net loss per share, basic and diluted (0.08 ) (0.08 ) (0.08 ) (0.08 ) Fiscal Year 2021 December 31, September 30, June 30, March 31, Revenue $ 557 $ 718 $ 746 $ 479 Gross profit 509 728 777 484 Net loss (12,625 ) (9,382 ) (14,962 ) (6,231 ) Net loss per share, basic and diluted (0.08 ) (0.06 ) (0.09 ) (0.04 ) Fiscal Year 2020 December 31, September 30, June 30, March 31, Revenue $ 395 $ 639 $ 587 $ 1,469 Gross profit 395 639 588 70 Net loss (3,570 ) (2,826 ) (2,304 ) (4,934 ) Net loss per share, basic and diluted (0.02 ) (0.02 ) (0.02 ) (0.04 ) |
Schedule II (Tables)
Schedule II (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule of Valuation Allowance for Impairment of Recognized Servicing Assets [Table Text Block] | MicroVision, Inc. Valuation and Qualifying Accounts and Reserves Schedule (In thousands) Additions Balance at Charges Charges Balance beginning of to costs and to other at end of Year Ended December 31, fiscal period expenses accounts Deductions fiscal period 2020 Tax valuation allowance $ 117,725 $ — $ — $ (3,318 ) $ 114,407 2021 Tax valuation allowance $ 114,407 $ 9,973 $ — $ — $ 124,380 2022 Tax valuation allowance $ 124,380 $ 5,745 $ — $ — $ 130,125 |
1. THE COMPANY AND LIQUIDITY (D
1. THE COMPANY AND LIQUIDITY (Details Narrative) $ in Thousands, € in Millions | 12 Months Ended | ||||||
Jan. 31, 2023 USD ($) | Jan. 31, 2023 EUR (€) | Dec. 01, 2022 USD ($) | Dec. 01, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Cash and Cash Equivalents, at Carrying Value | $ 18,500 | $ 20,536 | $ 82,647 | $ 16,862 | |||
Available-for-sale Securities | 59,200 | ||||||
Payments to Acquire Productive Assets | 4,132 | $ 0 | $ 0 | ||||
Ibeo Automotive Systems GmbH [Member] | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Payments to Acquire Productive Assets | 7,600 | € 7 | $ 7,100 | € 6.6 | |||
Escrow Deposit Disbursements Related to Property Acquisition | $ 3,300 | € 3 | |||||
Payments to Acquire Productive Assets | $ 4,100 |
2. SUMMARY OF SIGNIFICANT ACC_4
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Product Information [Line Items] | |||||||||||||||
[custom:LetterOfCreditForFutureLease-0] | $ 657,000 | $ 657,000 | |||||||||||||
[custom:LetterOfCreditForCurrentLease-0] | 305,000 | 305,000 | |||||||||||||
Revenues | 0 | $ 0 | $ 314,000 | $ 350,000 | $ 557,000 | $ 718,000 | $ 746,000 | $ 479,000 | $ 395,000 | $ 639,000 | $ 587,000 | $ 1,469,000 | 664,000 | $ 2,500,000 | $ 3,090,000 |
[custom:LetterOfCreditForPastLease-0] | $ 457,000 | 457,000 | |||||||||||||
Microsoft Concentration Risk [Member] | |||||||||||||||
Product Information [Line Items] | |||||||||||||||
Revenues | $ 664,000,000 | $ 2,500,000 | $ 3,000,000 | ||||||||||||
Microsoft Concentration Risk [Member] | Concentration of major customers and suppliers [Member] | |||||||||||||||
Product Information [Line Items] | |||||||||||||||
Concentration Risk, Percentage | 100% | 100% | |||||||||||||
Microsoft Concentration Risk [Member] | Concentration of major customers and suppliers [Member] | Maximum [Member] | |||||||||||||||
Product Information [Line Items] | |||||||||||||||
Concentration Risk, Percentage | 97% |
Schedule of Earnings Per Share,
Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | |||||||||||||||
Net loss available for common shareholders | $ (13,475) | $ (12,851) | $ (13,597) | $ (13,168) | $ (12,625) | $ (9,382) | $ (14,962) | $ (6,231) | $ (3,570) | $ (2,826) | $ (2,304) | $ (4,934) | $ (53,091) | $ (43,200) | $ (13,634) |
Weighted Average Number of Shares Outstanding, Basic | 165,958 | 160,662 | 139,829 | ||||||||||||
Weighted Average Number of Shares Outstanding, Diluted | 165,958 | 160,662 | 139,829 | ||||||||||||
Earnings Per Share, Basic | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.06) | $ (0.09) | $ (0.04) | $ (0.02) | $ (0.02) | $ (0.02) | $ (0.04) | $ (0.32) | $ (0.27) | $ (0.1) |
Earnings Per Share, Diluted | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.06) | $ (0.09) | $ (0.04) | $ (0.02) | $ (0.02) | $ (0.02) | $ (0.04) | $ (0.32) | $ (0.27) | $ (0.1) |
Schedule of Antidilutive Securi
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 9,811 | 4,158 | 5,263 |
Share-based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 945 | 1,533 | 3,281 |
Restricted Stock Units (RSUs) [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 8,866 | 2,625 | 1,982 |
Expensed Share-based Payments (
Expensed Share-based Payments (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Noncash Expense | $ 15,461 | $ 15,284 | $ 1,297 |
Research and Development Expense [Member] | |||
Share-based Payment Arrangement, Noncash Expense | 6,933 | 6,125 | 699 |
Selling, General and Administrative Expenses [Member] | |||
Share-based Payment Arrangement, Noncash Expense | $ 8,528 | $ 9,159 | $ 598 |
3. REVENUE RECOGNITION (Details
3. REVENUE RECOGNITION (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Apr. 17, 2017 | |
Disaggregation of Revenue [Line Items] | |||
Accrued Liabilities for Commissions, Expense and Taxes | $ 0 | ||
Contract with Customer, Liability | 4,601,000 | $ 5,265,000 | |
License [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Deferred Revenue | $ 10,000,000 | ||
Contract with Customer, Liability, Revenue Recognized | 5,400,000 | $ 664,000 | |
Contract with Customer, Liability | $ 4,600,000 |
Disaggregation of Revenue (Deta
Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disaggregation of Revenue [Line Items] | |||
[custom:TimingOfRevenueRecognition] | Timing of revenue recognition | Timing of revenue recognition: | Timing of revenue recognition: |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 664 | $ 2,500 | $ 3,090 |
Product Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 1,347 |
License And Royalty Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 664 | 2,500 | 1,718 |
Contract Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 25 |
Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 664 | 2,500 | 3,069 |
Transferred at Point in Time [Member] | Product Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 1,347 |
Transferred at Point in Time [Member] | License And Royalty Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 664 | 2,500 | 1,718 |
Transferred at Point in Time [Member] | Contract Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 4 |
Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 21 |
Transferred over Time [Member] | Product Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 |
Transferred over Time [Member] | License And Royalty Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 |
Transferred over Time [Member] | Contract Revenue [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 | $ 0 | $ 21 |
Significant Changes in Contract
Significant Changes in Contract Assets and Contract Liabilities (Details) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Accrued Liabilities, Current | $ 2,058 | $ 1,170 | |
Contract liabilities | 4,601 | 5,265 | $ 7,765 |
Contract with Customer, Asset, after Allowance for Credit Loss, Current | 0 | 0 | |
[custom:ContractWithCustomerAssetNetCurrentChange] | $ 0 | ||
[custom:ContractWithCustomerAssetNetCurrentPercentChange] | 0 | ||
Contract with Customer, Liability, Current | $ (4,601) | (5,265) | (7,765) |
[custom:ContractWithCustomerLiabilityCurrentChange] | $ 664 | ||
[custom:ContractWithCustomerLiabilityCurrentPercentChange] | 12.6 | ||
[custom:ContractWithCustomerAssetandLiabilitiesNet-0] | $ (4,601) | (5,265) | |
[custom:ContractWithCustomerAssetandLiabilitiesNetChange] | $ 664 | ||
[custom:ContractWithCustomerAssetandLiabilitiesNetPercentChange] | 12.6 | ||
Continuing Operations [Member] | |||
Accounts Receivable, after Allowance for Credit Loss, Current | $ 0 | 0 | 0 |
Accrued Liabilities, Current | 0 | 0 | 0 |
Deferred revenue | $ 0 | $ 0 | $ 0 |
Schedule of Fair Value Hierarch
Schedule of Fair Value Hierarchy Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | $ 62,173 | $ 32,720 |
Corporate Debt Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 15,500 | 32,720 |
US Treasury Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 46,673 | |
Fair Value, Recurring [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Current | 62,173 | 32,720 |
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 15,500 | 32,720 |
Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 46,673 | |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Current | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 0 | |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Current | 62,173 | 32,720 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 15,500 | 32,720 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 46,673 | |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Current | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | 0 | $ 0 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Debt Securities, Available-for-sale, Current | $ 0 |
Schedule of Unrealized Gain or
Schedule of Unrealized Gain or Loss on Short-term Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost, Current | $ 62,300 | $ 32,739 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | 2 | 3 |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (129) | (22) |
Debt Securities, Available-for-sale, Current | 62,173 | 32,720 |
Corporate Debt Securities [Member] | ||
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost, Current | 15,538 | 32,739 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | 0 | 3 |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (38) | (22) |
Debt Securities, Available-for-sale, Current | 15,500 | $ 32,720 |
US Treasury Securities [Member] | ||
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost, Current | 46,762 | |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | 2 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (91) | |
Debt Securities, Available-for-sale, Current | $ 46,673 |
+Maturity Date of Available-for
+Maturity Date of Available-for-sale Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Debt Securities Heldtomaturity Allowance For Credit Loss Line Items | ||
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $ 2 | $ 3 |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (129) | (22) |
Debt Securities, Available-for-sale, Amortized Cost, Current | 62,300 | 32,739 |
Debt Securities, Available-for-sale, Current | 62,173 | 32,720 |
Corporate Debt Securities [Member] | ||
Debt Securities Heldtomaturity Allowance For Credit Loss Line Items | ||
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost | 32,739 | |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | 0 | 3 |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (38) | (22) |
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value | 32,720 | |
Debt Securities, Available-for-sale, Amortized Cost, Current | 15,538 | 32,739 |
Debt Securities, Available-for-sale, Current | 15,500 | $ 32,720 |
Corporate Debt and US Treasury Securities [Member] | ||
Debt Securities Heldtomaturity Allowance For Credit Loss Line Items | ||
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost | 62,300 | |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | 2 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (129) | |
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value | $ 62,173 |
Schedule of Unrealized Loss on
Schedule of Unrealized Loss on Investment Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule Of Investment Income Reported Amounts By Category [Line Items] | ||
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months | $ 46,825 | $ 27,195 |
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | (129) | (22) |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer | 0 | 0 |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | 0 | 0 |
Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value | 46,825 | 27,195 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (129) | (22) |
Corporate Debt Securities [Member] | ||
Schedule Of Investment Income Reported Amounts By Category [Line Items] | ||
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months | 12,295 | 27,195 |
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | (38) | (22) |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer | 0 | 0 |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | 0 | 0 |
Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value | 12,295 | 27,195 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (38) | $ (22) |
US Treasury Securities [Member] | ||
Schedule Of Investment Income Reported Amounts By Category [Line Items] | ||
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months | 34,530 | |
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | (91) | |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer | 0 | |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | 0 | |
Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value | 34,530 | |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $ (91) |
5. INVENTORY (Details Narrative
5. INVENTORY (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Inventory Disclosure Abstract | |||
Inventory write-down | $ 87,000 | $ 48,000 | $ 168,000 |
Components of Inventory (Detail
Components of Inventory (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure Abstract | ||
Raw materials | $ 1,556 | $ 1,780 |
Work in process | 305 | 0 |
Total Inventory | $ 1,861 | $ 1,780 |
Table of Accrued Liabilities (D
Table of Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Payables And Accruals Abstract | ||
Bonuses | $ 537 | $ 43 |
Payroll and payroll taxes | 766 | 601 |
Accrued professional fees | 378 | 89 |
Liabilities to suppliers | 130 | 263 |
Other | 247 | 174 |
Accrued liabilities | $ 2,058 | $ 1,170 |
7. PROPERTY AND EQUIPMENT (Deta
7. PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property Plant And Equipment Abstract | |||
Depreciation expense | $ 705,000 | $ 902,000 | $ 442,000 |
Components of Property, Plant a
Components of Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Property Plant And Equipment Abstract | ||
Machinery and Equipment, Gross | $ 6,140 | $ 8,224 |
Leasehold Improvements, Gross | 3,789 | 913 |
Property, Plant and Equipment, Other, Gross | 10,515 | 7,230 |
Office furniture and equipment | 1,804 | 1,372 |
Property, gross | 22,248 | 17,739 |
Less: Accumulated depreciation | (15,418) | (14,713) |
Property, net | $ 6,830 | $ 3,026 |
8. INTANGIBLE ASSETS (Details N
8. INTANGIBLE ASSETS (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill And Intangible Assets Disclosure Abstract | |||
Finite-Lived Intangible Assets, Gross | $ 951,000 | $ 951,000 | |
Amortization of Intangible Assets | $ 40,000 | $ 49,000 | $ 57,000 |
Estimated Future Amortization E
Estimated Future Amortization Expense Related to Intangible Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Goodwill And Intangible Assets Disclosure Abstract | ||
2023 | $ 32 | |
2024 | 22 | |
2025 | 14 | |
2026 | 7 | |
Total | $ 75 | $ 115 |
9. COMMON STOCK (Details Narrat
9. COMMON STOCK (Details Narrative) - USD ($) $ in Thousands, shares in Millions | 1 Months Ended | 12 Months Ended | |||
Jan. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Feb. 28, 2023 | |
Class of Stock [Line Items] | |||||
Cash received from stock sale | $ 13,999 | $ 129,026 | $ 24,368 | ||
Common Stock, Value, Outstanding | $ 43,500 | ||||
June 2021 [Member] | |||||
Class of Stock [Line Items] | |||||
Stock agreement terms and provisions | In June 2021, we entered into a $140.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we are able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $140.0 million through Craig-Hallum. In 2021, we had issued 4.0 million shares of our common stock for net proceeds of $67.8 million under this ATM agreement. In 2022, we issued 4.3 million shares of our common stock for net proceeds of $14.0 million under this ATM agreement. In January 2023, we issued 5.0 million shares of our common stock for net proceeds of $12.5 million under the agreement. As of February 28, 2023, we have approximately $43.5 million available under this ATM agreement. | ||||
Number of shares of common stock issued | 5 | 4.3 | 4 | ||
Cash received from stock sale | $ 12,500 | $ 14,000 | $ 67,800 | ||
February 2021 [Member] | |||||
Class of Stock [Line Items] | |||||
Stock agreement terms and provisions | In February 2021, we entered into a $50.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $50.0 million through Craig-Hallum. We issued 2.5 million shares of our common stock for net proceeds of $48.8 million under this ATM agreement. No further shares are available for sales under this agreement. | ||||
Number of shares of common stock issued | 2.5 | ||||
Cash received from stock sale | $ 48,800 | ||||
December 2020 [Member] | |||||
Class of Stock [Line Items] | |||||
Stock agreement terms and provisions | In December 2020, we entered into a $13.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, from time to time, at our discretion to offer and sell shares of our common stock having an aggregate value of up to $13.0 million through Craig-Hallum. As of December 31, 2020, we had issued 1.0 million shares for net proceeds of $6.1 million that was received in January 2021. The $6.1 million was classified as subscriptions receivable on our December 31, 2020 balance sheet and is not included in the cash balance as of December 31, 2020. In January 2021, we issued 1.1 million shares of our common stock for net proceeds of $6.6 million under the agreement. In total, we issued 2.1 million shares of our common stock for net proceeds of $12.7 million under this ATM agreement. No further shares are available for sales under this agreement. | ||||
Number of shares of common stock issued | 2.1 | ||||
Cash received from stock sale | $ 12,700 |
10. SHARE-BASED COMPENSATION (D
10. SHARE-BASED COMPENSATION (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Mar. 31, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based compensation arrangement by share-based payment award, number of shares available for grant | 12,700,000 | 12,700,000 | ||||
TotalGrantDateFairValueOfOptionsVested | $ 115,000 | $ 508,000 | $ 604,000 | |||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 1,000 | $ 1,000 | ||||
Amortization period | 1 year 2 months 12 days | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 9,180,000 | 4,179,000 | 1,462,000 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 1,548,000 | 1,157,000 | 475,000 | |||
Employee Stock Option Member | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based compensation arrangement by share-based payment award, number of shares authorized | 20,000,000 | 20,000,000 | ||||
Share-based compensation arrangement by share-based payment award, number of shares available for grant | 3,500,000 | |||||
Restricted Stock Units (RSUs) [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Amortization period | 1 year 7 months 6 days | |||||
Unrecognized share-based employee compensation | $ 13,100,000 | $ 13,100,000 | ||||
Restricted Stock Units (RSUs) [Member] | C E O Grant [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In 2021, an equity award was granted to the Chief Executive Officer in the form of 1.2 million restricted stock units. These shares were valued based on the closing price of our common stock on the dates of grant. On the date of grant, 300,000 shares vested immediately, 300,000 vested in April 2022 and subsequent grants of 300,000 RSUs will be made on an annual basis in each of April 2023 and April 2024. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 1,200,000 | |||||
Restricted Stock Units (RSUs) [Member] | R S Uto Non Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In 2021, we issued 1.1 million RSUs to non-executive employees for promotion, retention and new hire grants. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest annually over one to four years from the date of grant. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 1,100,000 | |||||
Restricted Stock Units (RSUs) [Member] | R S Uto Retentionand New Hire Non Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In 2022, we issued 570,000 time-based RSUs to non-executive employees for promotion, retention, and new hire grants. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest over three or four years from the date of grant. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 570,000 | |||||
Performance Shares Member | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Amortization period | 1 year | |||||
Performance Shares Member | Share Based Payment Arrangement Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Amortization period | 2 years 8 months 12 days | |||||
Unrecognized share-based employee compensation | $ 7,900,000 | $ 7,900,000 | ||||
Performance Shares Member | Share Based Payment Arrangement Non Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based compensation arrangement by share-based payment award, number of shares authorized | 2,000,000 | 2,000,000 | ||||
Performance Shares Member | P S Uto Non Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In 2021, we issued 1.5 million shares of performance stock units to non-executive employees. These shares were valued based on the closing price of our common stock on the dates of grant. The shares vest one-eighth upon achievement of performance milestones with the remainder vesting quarterly over the following seven quarters. In 2021, 1.1 million of the performance stock units were canceled because of modifications to or failure to achieve performance milestones. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 1,500,000 | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 1,100,000 | |||||
Performance Shares Member | P S Uto Non Executive [Member] | Share Based Payment Arrangement Non Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In 2022, we issued 2.4 million PSUs to non-executive employees subject to the achievement of development goals. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest quarterly over two years from the achievement of established performance criteria. We canceled 426,000 PSUs in the fourth quarter of 2022 and re-issued 106,000 PSUs in the first quarter of 2023 due to partial achievement of internal performance milestones. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 2,400,000 | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 106,000 | 426,000 | ||||
Performance Shares Member | P S Uto Executives [Member] | Share Based Payment Arrangement Executive [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award | In June 2022, we issued 6.0 million PSUs to our executive officers. The PSUs are subject to the achievement of performance goals and time-based vesting. The PSUs will become eligible to vest if the closing price of our common stock reaches or exceeds specified price thresholds for at least 20 consecutive trading days during the performance period through December 31, 2025. If the performance goals are met, the portion of the PSUs deemed earned will become subject to time-based vesting in equal quarterly installments over two years starting from the date on which the goal is achieved. These PSUs were valued using a Monte Carlo simulation model using the following inputs: stock price, volatility, and risk-free interest rates. | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | 6,000,000 |
Schedule of Valuation Assumptio
Schedule of Valuation Assumptions for Weighted-Average Grant (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Volatility | 0% | 120% | 111% | |
Expected term (in years) | 4 years | 4 years | ||
Risk-free rate | 0% | 0.90% | 0.30% | |
Expected dividends | 0% | 0% | 0% | |
PrevestForfeitureRate | 0% | 8.50% | 8.50% | |
Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price | $ 0 | $ 11.72 | $ 1.2 | |
Employee Stock Option Member | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Share-based compensation arrangement by share-based payment award, options, outstanding, number, beginning balance | 1,533,000 | 3,281,000 | 5,104,000 | |
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price, beginning balance | $ 1,370 | $ 1,510 | $ 1,660 | |
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term | 5 years 8 months 12 days | 5 years 7 months 6 days | 6 years 7 months 6 days | 7 years 4 months 24 days |
Share-based compensation arrangement by share-based payment award, options, grants in period, gross | 0 | 8,000 | 68,000 | |
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price | $ 0 | $ 14,040 | $ 1,600 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | (525,000) | (1,519,000) | (693,000) | |
Share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price | $ 1,380 | $ 1,750 | $ 1,440 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | (63,000) | (237,000) | (1,198,000) | |
Share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price | $ 3,000 | $ 1,230 | $ 2,200 | |
Share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value | $ 1,137 | $ 5,645 | $ 12,784 | $ 122 |
Share-based compensation arrangement by share-based payment award, options, outstanding, number, ending balance | 945,000 | 1,533,000 | 3,281,000 | 5,104,000 |
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price, ending balance | $ 1,260 | $ 1,370 | $ 1,510 | $ 1,660 |
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number | 945,000 | |||
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price | $ 1,260 | |||
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average remaining contractual term | 5 years 8 months 12 days | |||
Share-based compensation arrangement by share-based payment award, options, aggregate intrinsic value | $ 1,136 | |||
Share-based compensation arrangement by share-based payment award, options, exercisable, number | 941,000 | |||
Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price | $ 1,260 | |||
Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term | 5 years 8 months 12 days | |||
Share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value | $ 1,129 |
Schedule of Activity And Positi
Schedule of Activity And Positions With Respect To RSUs And PSUs (Details) - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments Abstract | |||
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, beginning balance | 2,625 | 1,983 | 1,215 |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, weighted average grant date fair value , beginning balance | $ 13,050 | $ 760 | $ 400 |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period | 9,180 | 4,179 | 1,462 |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value | $ 2,460 | $ 12,920 | $ 1,080 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | (1,391) | (2,380) | (219) |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, weighted average grant date fair value | $ 9,160 | $ 3,110 | $ 880 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | (1,548) | (1,157) | (475) |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value | $ 6,420 | $ 11,970 | $ 770 |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, ending balance | 8,866 | 2,625 | 1,983 |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, weighted average grant date fair value, ending balance | $ 3,850 | $ 13,050 | $ 760 |
Components of Lease Expense (De
Components of Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Leases [Abstract] | |||
Operating Lease, Expense | $ 1,501 | $ 513 | $ 464 |
Finance lease expense: | |||
Finance Lease, Right-of-Use Asset, Amortization | 26 | 30 | 26 |
Finance Lease, Interest Expense | 2 | 3 | 3 |
Total finance lease expense | 28 | 33 | 29 |
Total lease expense | $ 1,529 | $ 546 | $ 493 |
Cash Flow Information Related t
Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash paid for amounts included in measurement of lease liabilities: | |||
Operating Lease, Payments | $ 1,280 | $ 762 | $ 656 |
Finance Lease, Interest Payment on Liability | 2 | 3 | 3 |
Finance Lease, Principal Payments | 26 | 28 | 29 |
Right-of-use assets obtained in exchange for new lease obligations: | |||
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 10,184 | 5,322 | $ 0 |
Leases, Operating [Abstract] | |||
Operating lease right-of-use assets | 14,579 | 5,577 | |
Operating Lease, Liability | 15,675 | ||
Finance leases | |||
Property, Plant and Equipment, Gross | 22,248 | 17,739 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | (15,418) | (14,713) | |
Property, Plant and Equipment, Net | 6,830 | 3,026 | |
Finance Lease, Liability | $ 21 | $ 47 | |
Weighted Average Remaining Lease Term | |||
Operating Lease, Weighted Average Remaining Lease Term | 13 years 1 month 6 days | 9 years 6 months | |
Finance Lease, Weighted Average Remaining Lease Term | 6 months | 1 year 2 months 12 days | |
Weighted Average Discount Rate | |||
Operating leases | 9% | 2.50% | |
Finance Lease, Weighted Average Discount Rate, Percent | 6.30% | 6.30% | |
Financial Lease [Member] | |||
Finance leases | |||
Property, Plant and Equipment, Gross | $ 112 | $ 112 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | (80) | (56) | |
Property, Plant and Equipment, Net | 32 | 56 | |
Other Current Liabilities [Member] | |||
Leases, Operating [Abstract] | |||
Operating Lease, Liability | 1,846 | 849 | |
Finance leases | |||
Finance Lease, Liability | 21 | 21 | |
Other Noncurrent Liabilities [Member] | |||
Leases, Operating [Abstract] | |||
Operating Lease, Liability | 13,829 | 4,983 | |
Finance leases | |||
Finance Lease, Liability | 0 | 26 | |
Other Liabilities [Member] | |||
Leases, Operating [Abstract] | |||
Operating Lease, Liability | $ 15,675 | $ 5,832 |
Maturities of Lease Liabilities
Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Operating Lease,2023 | $ 1,904 | |
Finance Lease,2023 | 22 | |
Operating Lease,2024 | 1,896 | |
Finance Lease,2024 | 0 | |
Operating Lease,2025 | 1,947 | |
Finance Lease,2025 | 0 | |
Operating Lease,2026 | 2,000 | |
Finance Lease,2026 | 0 | |
Operating Lease,thereafter | 11,642 | |
Finance Lease,thereafter | 0 | |
Operating leases, total mimimum lease payments | 19,389 | |
Finance Lease, total mimimum lease payments | 22 | |
Operating leases, less amount representing interest | (3,714) | |
Finance leases, less amount representing interest | (1) | |
Operating Lease, Liability | 15,675 | |
Finance Lease, Liability | $ 21 | $ 47 |
11. LEASES (Details Narrative)
11. LEASES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2022 | |
Lessee, Lease, Description [Line Items] | |||
Operating lease right-of-use asset | $ 9,300,000 | ||
Finance Lease, Description | Our finance leases contain options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless we are reasonably certain to exercise the purchase option. | ||
Lessee, Operating Lease, Liability, to be Paid, Year One | $ 1,904,000 | ||
Office Lease [Member] | |||
Lessee, Lease, Description [Line Items] | |||
Lessee, Operating Lease, Description | In September 2021, we entered into an office lease with Redmond East Office Park LLC, a Washington limited liability company, pursuant to which we will lease approximately 16,681 square feet of space located in Redmond, Washington that we will use primarily for general office space and product testing. The lease provides for an initial term of 128 months that commenced November 1, 2021. Pursuant to the lease, annual base rent will be approximately $500,000 for the first year and is subject to annual increases of 3.0%. In addition to base rent, we will pay additional rent comprised of our proportionate share of any operating expenses, real estate taxes, and management fees. We have the option to extend the term for one ten-year renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $6.4 million. | ||
Lessee, Operating Sublease, Option to Extend | We have the option to extend the term for one ten-year renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $6.4 million. | ||
Second Office Lease [Member] | |||
Lessee, Lease, Description [Line Items] | |||
Lessee, Operating Lease, Description | In September 2021, we entered into a second office lease with Redmond East Office Park LLC, pursuant to which we will lease approximately 36,062 square feet of space located in Redmond, Washington that we will use primarily for general office and lab space. The lease provides for an initial term of 120 months and commenced on December 1, 2022. Pursuant to the lease, annual base rent will be approximately $1.1 million for the first year and is subject to annual increases of 3.0%. In addition to base rent, we will pay additional rent comprised of our proportionate share of any operating expenses, real estate taxes, and management fees. We have the option to extend the term for one ten-year renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $13.0 million. The delivery date of the new space was September 1, 2022 to allow for the build out of tenant improvements before the commencement date. During the quarter ended September 30, 2022, we recorded a right-of-use asset in the amount of $9.3 million on our balance sheet. | ||
Lessee, Operating Sublease, Option to Extend | We have the option to extend the term for one ten-year renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $13.0 million. | ||
Current Office Lease [Member] | |||
Lessee, Lease, Description [Line Items] | |||
Lessee, Operating Lease, Description | In connection with the effectiveness of the second lease with Redmond East Office Park, we amended our current office lease and will have access until January 31, 2023 to coincide with our move into the new 36,062 square feet of space. | ||
Nuremberg Office Lease [Member] | |||
Lessee, Lease, Description [Line Items] | |||
Lessee, Operating Lease, Description | In September 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,810 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced November 15, 2022. Pursuant to the lease, annual base rent is approximately $92,000 per year. The total minimum lease payments related to this lease is approximately $461,000. | In April 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,533 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced May 1, 2022. Pursuant to the lease, annual base rent is approximately $76,000 per year. The total minimum lease payments related to this lease is approximately $380,000. | |
Lessee, Operating Lease, Liability, to be Paid, Year One | $ 461,000 | $ 461,000 | $ 380,000 |
Schedule of Effective Income Ta
Schedule of Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure Abstract | |||
Statutory rate | 21% | 21% | 21% |
Compensation related | (0.50%) | (8.20%) | 0% |
Share-based compensation | (2.20%) | 25.10% | 0% |
Net operating loss expiration | (9.00%) | (16.20%) | (47.50%) |
Tax credits | 1.50% | 1.40% | 2.20% |
Change in valuation allowance | (10.80%) | (23.10%) | 24.30% |
Total | 0% | 0% | 0% |
Schedule of Deferred Tax Assets
Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Components of Deferred Tax Assets [Abstract] | ||
Reserves | $ 651 | $ 634 |
Net operating loss carryforwards | 92,469 | 90,593 |
R&D credit carryforwards | 9,628 | 8,984 |
Depreciation/amortization deferred | 19,787 | 17,417 |
Other | 7,360 | 6,701 |
Total deferred tax assets | 133,187 | 125,551 |
Operating Lease Liabilities | 3,292 | 1,222 |
Components of Deferred Tax Liabilities [Abstract] | ||
Operating lease right-of-use assets | (3,062) | (1,171) |
Total deferred tax liabilities | (3,062) | (1,171) |
Net valuation allowances | (130,125) | (124,380) |
Deferred tax assets | $ 0 | $ 0 |
13. INCOME TAXES (Details Narra
13. INCOME TAXES (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | |||
Income Tax Expense (Benefit) | $ 0 | $ 0 | $ 0 |
Other Information Pertaining to Income Taxes | During 2022, $22.0 million federal net operating losses and $171,000 general business credits expired unused. | ||
Operating Loss Carryforwards, Limitations on Use | In certain circumstances, as specified in the Internal Revenue Code, a 50% or more ownership change by certain combinations of our shareholders during any three year period would result in limitations on our ability to use a portion of our net operating loss carryforwards. | ||
Unrecognized Tax Benefits | $ 0 | 0 | |
Income Tax Examination, Penalties and Interest Expense | $ 0 | $ 0 | $ 0 |
Open Tax Year | 1998 | ||
Minimum [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Dec. 31, 2022 | ||
Maximum [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Dec. 31, 2041 | ||
Research Tax Credit Carryforward [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Tax Credit Carryforward, Amount | $ 9,600,000 | ||
Domestic Tax Authority [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Operating Loss Carryforwards | $ 440,300,000 |
14. RETIREMENT SAVINGS PLAN (De
14. RETIREMENT SAVINGS PLAN (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Postemployment Benefits [Abstract] | |||
Defined Contribution Plan, Cost | $ 411,000 | $ 259,000 | $ 213,000 |
Quarterly Financial Information
Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |||||||||||||||
Revenue | $ 0 | $ 0 | $ 314 | $ 350 | $ 557 | $ 718 | $ 746 | $ 479 | $ 395 | $ 639 | $ 587 | $ 1,469 | $ 664 | $ 2,500 | $ 3,090 |
Gross profit | (33) | (45) | 296 | 346 | 509 | 728 | 777 | 484 | 395 | 639 | 588 | 70 | 564 | 2,498 | 1,692 |
Net loss | $ (13,475) | $ (12,851) | $ (13,597) | $ (13,168) | $ (12,625) | $ (9,382) | $ (14,962) | $ (6,231) | $ (3,570) | $ (2,826) | $ (2,304) | $ (4,934) | $ (53,091) | $ (43,200) | $ (13,634) |
Net loss per share, basic | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.06) | $ (0.09) | $ (0.04) | $ (0.02) | $ (0.02) | $ (0.02) | $ (0.04) | $ (0.32) | $ (0.27) | $ (0.1) |
Net loss per share, diluted | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.08) | $ (0.06) | $ (0.09) | $ (0.04) | $ (0.02) | $ (0.02) | $ (0.02) | $ (0.04) | $ (0.32) | $ (0.27) | $ (0.1) |
Schedule of Valuation Allowance
Schedule of Valuation Allowance for Impairment (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |||
Tax valuation allowance | $ 124,380 | $ 114,407 | $ 117,725 |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 5,745 | 9,973 | 0 |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 0 | 0 | 0 |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | 0 | 0 | (3,318) |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance | $ 130,125 | $ 124,380 | $ 114,407 |
16. SUBSEQUENT EVENT (Details N
16. SUBSEQUENT EVENT (Details Narrative) $ in Thousands, € in Millions | 3 Months Ended | 12 Months Ended | |||||||
Jan. 31, 2023 USD ($) | Jan. 31, 2023 EUR (€) | Dec. 01, 2022 USD ($) | Dec. 01, 2022 EUR (€) | Jun. 30, 2023 USD ($) | Jun. 30, 2023 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Subsequent Event [Line Items] | |||||||||
Payments to Acquire Productive Assets | $ 4,132 | $ 0 | $ 0 | ||||||
Ibeo Automotive Systems GmbH [Member] | |||||||||
Subsequent Event [Line Items] | |||||||||
Asset Acquisition, Consideration Transferred | $ 16,100 | € 15 | |||||||
Payments to Acquire Productive Assets | $ 7,600 | € 7 | $ 7,100 | € 6.6 | |||||
Escrow Deposit Disbursements Related to Property Acquisition | 3,300 | 3 | |||||||
Payments to Acquire Productive Assets | $ 4,100 | ||||||||
Ibeo Automotive Systems GmbH [Member] | Subsequent Event [Member] | |||||||||
Subsequent Event [Line Items] | |||||||||
Payments to Acquire Productive Assets | $ 7,100 | € 6.6 | $ 7,600 | € 7 |